Bill > HR2438

This bill aims to modernize how new drugs and biological products are tested and reviewed by the Food and Drug Administration (FDA) by encouraging the use of advanced statistical methods. Specifically, it requires the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on incorporating "adaptive trial designs" and "Bayesian statistics" into clinical trials. Adaptive trial designs allow researchers to modify a study's direction based on interim results, making trials more efficient, while Bayesian statistics is a method of statistical inference that uses probability to represent uncertainty and can incorporate prior knowledge into analysis. The bill mandates updating existing draft guidance on adaptive trials and creating new draft guidance on Bayesian methods, both of which will cover how these methods can be used to meet the "substantial evidence standard" for drug approval, how sponsors can get early feedback on modeling and simulations, what information should be submitted for review, and recommended analysis techniques. Before finalizing this guidance, the Secretary must hold a public meeting with various stakeholders, including industry, academics, and patient groups, and the final guidance documents are to be published within specific timeframes after this meeting.